NEW YORK (GenomeWeb) – Sophia Genetics, a developer of bioinformatics for analyzing genetic test data, today said that it has raised $13.75 million in a Series B financing round.

The Lausanne, Switzerland-based company offers a software as a service called dropGen, which provides bioinformatic analyis, the validation and quality control process, and the presentation of genetic test results to clinicians while protecting patient DNA sequence data through safe storage and banking, it said.

The financing round was led by Invoke Capital, Swisscom, and Endeavour Vision.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
11
Sponsored by
ArcherDX

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.